Lv5
860 积分 2021-02-07 加入
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
3个月前
已完结
Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity
5个月前
已完结
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
6个月前
已完结
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
6个月前
已完结
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
6个月前
已完结
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
6个月前
已完结
Trends in the development of cellular and gene therapy in China
7个月前
已完结
Bayesian dose escalation with overdose and underdose control utilizing all toxicities in Phase I/II clinical trials
7个月前
已完结
The Efficacy and Safety of Ramucirumab in Heavily Pretreated Advanced Hepatocellular Carcinoma
7个月前
已完结
Sequencing Systemic Therapy in Hepatocellular Carcinoma
7个月前
已完结
皖公网安备34019202002308
